{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"SCYNEXIS, Inc."},"Symbol":{"label":"Symbol","value":"SCYX"},"Address":{"label":"Address","value":"1 EVERTRUST PLAZA,13TH FLOOR, JERSEY CITY, New Jersey, 07302 - 6548, United States"},"Phone":{"label":"Phone","value":"+1 201 884-5485"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains."},"CompanyUrl":{"label":"Company Url","value":"https://www.scynexis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daniella Gigante","title":"VP-Human Resources & Information Technology"},{"name":"David Angulo Gonzalez","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}